Doses studied, not doses recommended
Ipamorelin dosage, strictly as the studies reported it.
What was given, to which species, by which route — plus the half-life and the recurring reconstitution questions. No protocol, no recommendation.
Read this first
This page describes ipamorelin dosage only as it appears in published research — the amounts scientists gave to animals or to volunteers in controlled studies. It is not a how-to and not a recommendation, and you will not find a 'take this much' line anywhere on it. Why so careful? Because almost all of the dosing evidence is in rats, the one human trial used an IV hospital protocol that did not work [3], and the subcutaneous self-injection regimens people actually use have never been studied for safety or dose in humans. A quick gloss: 'half-life' just means how long it takes for half the drug to clear your blood. Ipamorelin's is about 2 hours in people [2]. Everything below is third-person, study-attributed, and cited.
Doses used in published studies
Here is the research-dose landscape, by study type. The human pharmacokinetic study gave single IV infusions of 4.21 to 140.45 nmol/kg over 15 minutes [2]. The human Phase 2 ileus trial used 0.03 mg/kg IV twice daily for up to 7 days [3]. In rats, the bone-growth study used 18, 90, and 450 micrograms/day subcutaneously, split three times daily [4]. The 2024 ferret cachexia study used 1-3 mg/kg intraperitoneally [5]. These are doses measured per kilogram of body weight in animals or in tightly monitored hospital settings — they are not numbers anyone should translate into a personal regimen, and they cannot be, because no validated human dose exists.
Half-life and how long it stays around
Ipamorelin's terminal half-life in healthy human volunteers is about 2 hours, with clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg [2]. The GH response it triggers is a single, discrete pulse that peaks roughly 40 minutes after dosing and then fades [2]. In rats, plasma clearance runs about 5-fold lower than GHRP-6, meaning it lingers a bit longer than that older peptide. Practically, this short half-life is also why ipamorelin is a moving target for anti-doping labs — a 2026 sport-medicine review specifically flagged the short half-life as an analytical challenge for detection [12].
Routes that have been studied
Different studies used different routes, and they are not equivalent. Intravenous dosing appears in the human PK and clinical-trial work and in rodent efficacy studies [2][3]. Subcutaneous injection dominates the rodent bone and body-composition research and is also the route most common in community use [4]. Intranasal delivery was tested in rats with roughly 20% bioavailability. Intraperitoneal dosing appears in rodent and ferret efficacy studies, including the 2024 ferret work [5]. Oral dosing only worked for engineered ipamorelin-derived analogs (around 10% in dogs) — ipamorelin itself is not orally bioavailable, so any 'oral ipamorelin' claim should be treated skeptically.
How much cjc-1295 ipamorelin should i take
There is no research-validated answer to how much cjc-1295 ipamorelin should i take, and this site will not invent one. The combination has never been tested in a controlled human trial, so no published dose exists for it as a unit. The community subcutaneous regimens circulating online have no peer-reviewed human dosing basis and are, by definition, anecdotal rather than recommended. What the literature does contain is single-agent pharmacology — ipamorelin's human half-life [2] and CJC-1295's separate dose-response data [3] — neither of which establishes a safe combined dose for a person. Anyone considering use should talk to a qualified clinician, not a forum.
How to reconstitute cjc-1295 ipamorelin 5mg
On how to reconstitute cjc-1295 ipamorelin 5mg, the honest framing is handling, not dosing. Ipamorelin is supplied as a lyophilized (freeze-dried) powder — either the free base or the acetate salt — and the research-supply literature describes reconstituting peptide powders with bacteriostatic water for handling [2]. As a peptide, it degrades with heat and repeated freeze-thaw cycles, so reconstituted solution is generally kept refrigerated. These are general peptide-handling observations from the supply literature, not a clinical preparation instruction and not a dosing protocol — the specific volumes and concentrations people quote online are unverified and outside any approved use.